Appointment of Joint Broker
No summary for this filing – the full text is below.
Select text to share a quote on X · sign in to keep highlights & notes in your SAR notes
Cambridge, UK, 18 December 2024 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, is pleased to announce the appointment of Oberon Capital as a Joint Corporate Broker with immediate effect. Oberon Capital is a trading name of Oberon Investments Limited.
Strand Hanson Limited and Hybridan LLP will continue to act as the Company's Nominated Adviser and Joint Corporate Broker, respectively.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.